Canaccord raised the firm’s price target on Privia Health (PRVA) to $29 from $26 and keeps a Buy rating on the shares. The firm said Privia delivered another quarter of executing its growth strategy that produced predictable results coming in ahead of expectations with implemented providers, practice collections, and revenue beating estimates.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRVA:
- Privia Health price target raised to $21 from $19 at Barclays
- Privia Health Group Reports Strong Q3 2024 Results
- Privia Health reports Q3 adjusted EPS 20c, consensus 5c
- Privia Health raises 2024 revenue view to high end of $1.60B-$1.675B view
- Humana or Privia: KeyBanc Selects the Superior Healthcare Service Stock to Buy